Centene CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NYSE
Centene Corporation reported a significant net loss of $6.6 billion in Q3 2025, primarily due to a $6.7 billion goodwill impairment, despite an 18% increase in total revenues.
NYSE
Centene Corporation reported a significant net loss in the second quarter of 2025, primarily driven by increased medical costs and a reduction in Marketplace risk adjustment revenue estimates, despite strong revenue growth.
NYSE
Centene Corporation announces a strong first quarter in 2025, with significant revenue growth and improved earnings per share, driven by its Medicare and Commercial segments.
NYSE
Centene Corporation's third-quarter results show revenue growth offset by increased medical costs and impacts from Medicaid redeterminations and Medicare Star ratings.
NYSE
Centene Corporation's second quarter results show a 6% year-over-year revenue increase, driven by Marketplace growth, while navigating Medicaid redeterminations.
NYSE
Centene Corporation's first quarter 2024 results show revenue growth and strategic adjustments amidst Medicaid redeterminations and divestitures.